To evaluate the clinical efficacy of robot radical Gastrectomy and laparoscopic radical Gastrectomy, patients with gastric adenocarcinoma (cT2N+M0 or cT3-4a/N+M0, phase II and III) undergoing neoadjuvant treatment were selected as subjects.
18 years old ≤ 75 years old male or female;
The primary gastric lesion was diagnosed as gastric adenocarcinoma (papillary adenocarcinoma, tubular adenocarcinoma, mucinous adenocarcinoma, Signet ring cell carcinoma, poorly differentiated adenocarcinoma) by endoscopic biopsy histopathology;
Before neoadjuvant treatment, the preoperative clinical staging was confirmed to be II and III (cT2N+M0 or cT3-4a/N+M0) through gastroscopy/ultrasound gastroscopy, enhanced CT/MR, or diagnostic laparoscopic exploration (based on AJCC-8th TNM tumor staging);
2-4 cycles of neoadjuvant therapy (chemotherapy+/- targeted/immunotherapy, simple chemotherapy);
Pregnant or lactating women;
Suffering from serious mental illness;
History of upper abdominal surgery (excluding history of laparoscopic cholecystectomy);
History of gastric surgery (excluding ESD/EMR for gastric cancer);
Parallel
Robotic radical gastrectomy
Procedure/SurgeryLaparoscopic gastrectomy
3-year disease-free survival
3-year disease-free survival
3-year overall survival rate
3-year overall survival rate
overall postoperative morbidity rates
overall postoperative morbidity rates
postoperative recovery course
postoperative recovery course
Click on the lead sponsor to view all of their trials.
